August 3, 2011
Half of the hepatitis C virus (HCV)-infected participants in a small midstage trial receiving a four-drug combination that included two Vertex Pharmaceuticals medications were able to discontinue treatment after 12 weeks, the company reported.
According to Vertex, 400 milligrams of its experimental oral drug VX-222 (a polymerase inhibitor) was administered with its recently approved Incivek (a protease inhibitor) and the standard regimen of pegylated interferon and ribavirin. The trial, known as Zenith, also revealed that 12 weeks after the combo discontinuation, 93 percent of those patients retained undetectable HCV levels.
Those patients not eligible to stop treatment at 12 weeks received another 12 weeks of standard therapy. All 13 who continued in the trial appeared cured at 24 weeks, Vertex said.
|This Week in HIV Research: Antibody Being Tested for HIV Prevention, and Differing Results on HCV Treatment in Coinfection|
|Which Hepatitis C Treatment to Start in 2016|
|What's the Most Overlooked Issue in HIV Care Today?|
|Using Saliva as Lube Can Cause Rectal Gonorrhea|
|This Week in HIV Research: When New Meets Old|